Research pavilion at MUHC named for Dr. Gold

MONTREAL – The pavilion housing the Research Institute of the McGill University Health Centre (RI-MUHC) at the Montreal General Hospital now bears the name of Dr. Phil Gold (pictured), in honour of his great contribution to science and to the community.

The news was announced by the Montreal General Hospital Foundation in a press release, as part of the Honouring Dr. Phil Gold campaign: 60 Years of Discovery, Innovation and Care.

Dr. Gold is a renowned clinician-scientist who, along with Dr. Samuel Freedman, discovered in 1965 the first biomarker for cancer, found in 70 percent of cancer patients. His exceptional 60-year career at the MGH is an immense source of pride.

A ribbon-cutting ceremony was held on June 5 at the Dr. Phil Gold Pavilion, marking the official naming of the building. Representatives of the McGill University Health Centre, the RI-MUHC, the Montreal General Hospital Foundation, and Dr. Gold’s family and colleagues attended the ceremony.

Dr. Phil Gold is a pioneer in cancer research, whose discovery of the first biomarker for cancer, the carcinoembryonic antigen (CEA), led to the development of the first blood test approved internationally for the detection and management of human cancer – the CEA blood test.

The RI-MUHC pavilion at the MGH was built using funds from the sale of his blood test to Roche in 1973.

His work has had a significant impact on the lives of countless cancer patients around the world, and his legacy will continue to inspire future generations of clinicians and researchers.